Stay updated on Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.4.2 replaces v3.4.1 as the page version. This is a minor update that does not change study content or eligibility details.SummaryDifference0.0%

- Check18 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1, with no user-facing changes to study content or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 removed, a minor UI/documentation update with no impact on the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedShow glossary was added and the page revision updated to v3.4.0; minor wording and capitalization adjustments were made to QC-related labels (Last Update Submitted that Met QC Criteria vs Last Update Submitted that met QC Criteria, and No FEAR Act Data vs No FEAR Act data). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedAn administrative update was made: Revision: v3.3.4 was added and Revision: v3.3.3 was removed, indicating an updated study documentation revision without altering core study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedDifference1%

Stay in the know with updates to Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial page.